<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03668028</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-114-18-01</org_study_id>
    <secondary_id>KCT0003174</secondary_id>
    <nct_id>NCT03668028</nct_id>
  </id_info>
  <brief_title>A Phase I/III Clinical Study of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear</brief_title>
  <official_title>A Multi-center, Randomized, Independent Evaluator-Subject Blinded, Placebo-Controlled, Phase I/III Clinical Study to Evaluate Safety and Efficacy of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tego Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tego Science, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rotator cuff tear is one of the most common shoulder diseases and retears occur frequently&#xD;
      after arthroscopic repair. Therefore, there is a growing need of new therapy to improve&#xD;
      structural outcome. This study evaluates the efficacy and safety of autologous fibroblasts&#xD;
      during arthroscopic repair. The primary outcome is the retear rate at 24 weeks after&#xD;
      administration of autologous fibroblasts (TPX-114) during arthroscopic repair. Secondary&#xD;
      outcomes are functional evaluations including Range of Motion (ROM), Constant Score (CS),&#xD;
      American Shoulder and Elbow Surgeons (ASES) score and Simple Shoulder Test (SST) at 24 and 52&#xD;
      weeks after administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retear Rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Retear rate assessed by an independent evaluator with MRI</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Rotator Cuff Injuries</condition>
  <arm_group>
    <arm_group_label>TPX-114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects undergo arthroscopic rotator cuff repair with TPX-114.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects undergo arthroscopic surgery for rotator cuff repair without TPX-114.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TPX-114</intervention_name>
    <description>Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.</description>
    <arm_group_label>TPX-114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arthroscopic surgery</intervention_name>
    <description>Subjects undergo conventional arthroscopic surgery for rotator cuff repair.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TPX-114</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must;&#xD;
&#xD;
          1. Be 19 years of age or older.&#xD;
&#xD;
          2. Require arthroscopic repair for full-thickness rotator cuff tear(&gt;2cm, â‰¤5cm) assessed&#xD;
             by MRI without improvement of symptoms despite more than 3 months of conservative&#xD;
             management.&#xD;
&#xD;
          3. Consent to undergo skin biopsy to manufacture test product.&#xD;
&#xD;
          4. Understand fully the study and voluntarily sign the informed consent for participation&#xD;
             in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants with any of the following conditions will be excluded unless stated otherwise;&#xD;
&#xD;
          1. Unsuitable for skin biopsy.&#xD;
&#xD;
          2. Have additional subscapularis tear.&#xD;
&#xD;
          3. Have prior medical history of the following at the time of screening.&#xD;
&#xD;
               -  Operation of the affected shoulder&#xD;
&#xD;
               -  Allergies to bovine proteins&#xD;
&#xD;
               -  Anaphylaxis to gentamicin&#xD;
&#xD;
               -  Coagulopathy&#xD;
&#xD;
               -  Genetic disorders affecting fibroblasts or collagen (ex. achondroplasia,&#xD;
                  osteogenesis imperfecta)&#xD;
&#xD;
               -  Malignant tumors within the last 5 years&#xD;
&#xD;
          4. Have been diagnosed with any of the following diseases at the time of screening.&#xD;
&#xD;
               -  Autoimmune disease (including RA)&#xD;
&#xD;
               -  HIV Ab-positive&#xD;
&#xD;
               -  Acute trauma, chronic shoulder dislocation, pyogenic infection on the affected&#xD;
                  shoulder&#xD;
&#xD;
               -  Scapulohumeral osteoarthritis&#xD;
&#xD;
          5. Be pregnant, breastfeeding, planning pregnancy or unwilling to use of contraceptives&#xD;
             suggested in this study.&#xD;
&#xD;
          6. Other surgical or nonsurgical procedures on the affected shoulder to be judged more&#xD;
             appropriate than arthroscopic repair.&#xD;
&#xD;
          7. Have participated in and received investigational agents in other clinical trials&#xD;
             within 4 weeks of this study.&#xD;
&#xD;
          8. Be deemed inadequate for the study by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo Han Oh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

